FDA says SoloVital's Umary supplement is an unapproved, misbranded drug containing hidden diclofenac and omeprazole.
What happened
FDA reviewed SoloVital's website in June 2024 and obtained samples and labeling of Umary, a product marketed as a dietary supplement. Laboratory analysis confirmed the sample contained undeclared diclofenac and omeprazole. The labeling did not disclose these drug ingredients, and FDA says the product is an unapproved new drug and misbranded.
What FDA found
The product is a new drug without an FDA-approved application.
Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)The labeling is false or misleading because it does not disclose diclofenac and omeprazole.
Section 502(a) of the FD&C Act, 21 U.S.C. 352(a)Selling this misbranded drug in interstate commerce is prohibited.
Section 301(a) of the FD&C Act, 21 U.S.C. 331(a)Umary is excluded from the dietary supplement definition because it contains diclofenac, an active ingredient in an approved drug marketed before diclofenac was sold as a supplement.
Sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i) and (ii)Website claims show the product is intended to treat or affect the body, making it a drug.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
What FDA wants
FDA asks SoloVital to notify it in writing within 15 working days of steps taken to correct the violations and prevent recurrence, including supporting documentation. If the company disagrees, it should include reasoning and supporting information.
Who should pay attention
- consumers who bought or use Umary
- retailers and online sellers offering Umary
- companies marketing dietary supplements with drug-like joint claims
This is a summary. Read the original letter on fda.gov.